Silex Systems Invites Shareholders to Join $15M Share Purchase Plan at Discounted Price

Context and Capital Raise

Silex Systems Limited (ASX, SLX), a company specialising in uranium enrichment technology, has announced a Share Purchase Plan (SPP) designed to raise up to $15 million from its existing shareholders in Australia and New Zealand. This initiative follows closely on the heels of a substantial $130 million institutional placement completed earlier in August 2025.

The SPP offers eligible shareholders the opportunity to purchase new shares at a price set at the lower of $3.90 per share; the price paid by institutional investors in the placement; or a 2% discount to the volume weighted average price (VWAP) over the five trading days leading up to the SPP’s closing date on 29 August 2025. This pricing mechanism aims to provide a fair entry point for retail investors while maintaining alignment with institutional pricing.

Participation and Terms

Eligible shareholders, defined as those registered by 7, 00pm AEST on 6 August 2025 with addresses in Australia or New Zealand, can apply for up to $30,000 worth of new shares without incurring brokerage or transaction fees. The offer explicitly excludes shareholders in the United States and those acting on behalf of U.S. persons, reflecting regulatory compliance considerations.

The SPP is not underwritten, meaning there is no guaranteed amount to be raised. Should demand exceed the $15 million target, the Silex Board retains discretion to scale back applications or increase the raise to a maximum of $20 million. Any scale-back would result in shareholders receiving fewer shares than applied for, with excess funds refunded without interest.

Use of Proceeds and Strategic Outlook

Proceeds from the combined $145 million capital raise (placement plus SPP) will primarily fund Silex’s 51% share in the commercialisation of its proprietary uranium enrichment technology through its U.S.-based exclusive licensee, Global Laser Enrichment LLC (GLE). Additionally, funds will support other isotope enrichment ventures, including Quantum Silicon and Medical Isotope Separation Technology, as well as general corporate purposes and working capital.

This capital injection is a critical step for Silex as it seeks to advance its technology from development towards commercial deployment, positioning itself within a niche but strategically important sector of the energy and nuclear technology markets.

Investor Considerations

Shareholders considering participation should be aware that the final issue price will only be determined after the SPP closes, introducing some uncertainty in the exact number of shares to be allocated. Market price fluctuations between the offer announcement and share issuance could affect the value of the investment. The offer is irrevocable once payment is made, and no cooling-off rights apply.

Craig Roy, Chair of Silex Systems, encourages shareholders to review the full terms and seek independent financial advice before participating. The company also reserves the right to amend the offer timetable or close the offer early, underscoring the dynamic nature of capital raising in the current market environment.